ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ATHE Alterity Therapeutics Limited

2.00
-0.04 (-1.96%)
After Hours
Last Updated: 21:36:49
Delayed by 15 minutes
Name Symbol Market Type
Alterity Therapeutics Limited NASDAQ:ATHE NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.04 -1.96% 2.00 1.90 2.21 2.10 1.90 2.04 44,669 21:36:49

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

29/01/2024 12:24pm

GlobeNewswire Inc.


Alterity Therapeutics (NASDAQ:ATHE)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more Alterity Therapeutics Charts.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the ShareCafe Hidden Gems webinar on the following dates/times:

AUSTRALIA PARTICIPANTS:Date:    Friday, 2 February 2024Time:    12:30 p.m. AEDT / 9:30 a.m. AWST

UNITED STATES PARTICIPANTS:Date:    Thursday, 1 February 2024Time:    5:30 p.m. PT / 8:30 p.m. ET

To access further details of the event and to register at no cost, please click here, or copy and paste the following link into your internet browser:https://us02web.zoom.us/webinar/register/WN_Xb_tWO_eR6yXkSyaMmqhrA#/registration

An archived replay will be made available following the event.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com.

Authorisation & Additional informationThis announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Investor and Media Contacts:

AustraliaHannah Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648 064

U.S.Remy Bernardaremy.bernarda@iradvisory.com +1 (415) 203-6386

1 Year Alterity Therapeutics Chart

1 Year Alterity Therapeutics Chart

1 Month Alterity Therapeutics Chart

1 Month Alterity Therapeutics Chart

Your Recent History

Delayed Upgrade Clock